Skip Navigation


Hum. Reprod. Advance Access originally published online on May 8, 2009
Human Reproduction 2009 24(8):1880-1890; doi:10.1093/humrep/dep175
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
24/8/1880    most recent
dep175v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Laudanski, P.
Right arrow Articles by Chyczewski, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laudanski, P.
Right arrow Articles by Chyczewski, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis

P. Laudanski1,4, J. Szamatowicz2, O. Kowalczuk3, M. Kuzmicki2, M. Grabowicz3 and L. Chyczewski3

1 Department of Perinatology, Medical University of Bialystok, ul. Marii Sklodowskiej-Curie 24a, Bialystok, Poland 2 Department of Gynecology, Medical University of Bialystok, ul. Marii Sklodowskiej-Curie 24 a, Bialystok, Poland 3 Department of Clinical Molecular Biology, Medical University of Bialystok, ul. Marii Sklodowskiej-Curie 24 a, Bialystok, Poland

4 Correspondence address. Department of Perinatology, Medical University of Bialystok, ul. Marii Sklodowskiej-Curie 24 a, Bialystok, Poland. Tel: +48-857468336; E-mail: plauda{at}umwb.edu.pl

BACKGROUND: It is becoming increasingly evident that the eutopic endometrium of women with endometriosis shows certain genetic alterations which are not found in the endometrium of disease-free women. The aim of the study was to compare the expression level of mammalian target of rapamycin (mTOR) tumor suppressor and oncogene-related genes in the endometrium of women with and without endometriosis as well as in ovarian endometriosis.

METHODS: A total of 81 regularly menstruating patients were recruited in the study. We applied the micro fluidic gene array to examine the expression of 15 human tumor suppressor and oncogenes in eutopic endometrium of 40 women with endometriosis and 41 controls without endometriosis. In 14 patients with endometriosis, gene expression was also studied in matched ovarian lesions. We studied the following genes: NF1, RHEB, mTOR, PTEN, TSC1, TSC2, KRAS, S6K1, TP53, EIF4E, LKB1, PIK3CA, BECN1, 4EBP1 and AKT1. Immunohistochemical studies were subsequently performed for selected proteins.

RESULTS: Of the 15 studied genes, we found significantly higher levels of oncogene AKT1 (P = 0.006) and tumor suppressor gene 4EBP1 (P = 0.01) mRNAs in the eutopic endometrium of women with endometriosis compared with control patients. Immunohistochemistry showed that 4EBP1 and AKT1 proteins were expressed in eutopic endometrium.

CONCLUSIONS: Our results suggest that up-regulation of AKT1 and 4EBP1 in eutopic endometrium may be associated with the pathogenesis of endometriosis, but their precise role remains to be established.

Key words: endometriosis/AKT1/4EBP1/eutopic endometrium/mTOR pathway

Submitted on October 7, 2008; resubmitted on April 1, 2009; accepted on April 16, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.